Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%

All products: general benefit

Other products in the same Health Canada class (A10AD) — coverage varies; not interchangeable

  • Insulin neutral + isophane human biosynthetic (Novolin ge 30/70): general benefit
  • Insulin human biosynthetic + isophane (Humulin 30/70): general benefit
  • Insulin lispro + insulin lispro protamine (Humalog Mix25): general benefit

NovoMix 30 Penfill · DIN 02265435 · 100U/mL · injectable suspension, 5 x 3 mL

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
NovoMix 30 Penfill · DIN 02265435 Manufacturer: Novo Nordisk Canada Inc; listing date 2007-11-10 Health Canada: Marketed since 2005-09-12 · brand NOVOMIX 30 · ATC A10AD05 INSULIN ASPART · form Suspension · route Subcutaneous · ingredients INSULIN ASPART 30 UNIT/ML, INSULIN ASPART PROTAMINE 70 UNIT/ML · company Novo nordisk canada inc · schedule Schedule d
Check this DIN again · Health Canada product record

NovoMix 30 Penfill: Formulary list price $60.6700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $60.6700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75090 · Verify on the e-Formulary ↗ (DIN 02265435)

Source record
DIN 02265435: NovoMix 30 Penfill Raw flags: insOH=Y, sec3=Y Item: 682016034; group id 784; item number 1908; lccId None; manufacturer id NOO Source form: Inj Susp-5x3mL Pk; strength: 100U/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $60.6700; ministry $60.6700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02265435 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75090
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:20:16 Insulins (Pre-Mixed)) and how they are covered

Matched class: 68:20:16 Insulins (Pre-Mixed)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70%, INSULIN LISPRO & INSULIN LISPRO PROTAMINE 68:20:16 Insulins (Pre-Mixed)

INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Susp-10mL Pk, Inj Susp-5x3mL Pk

INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70%

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Susp-10mL Pk, Inj Susp-5x3mL Pk

INSULIN LISPRO & INSULIN LISPRO PROTAMINE

· 4 products · General benefit · strengths: 25% & 75%, 50% & 50% · Inj Susp-5x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:16
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: diabetes
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN HUMAN BIOSYNTHETIC, INSULIN LISPRO & INSULIN LISPRO PROTAMINE INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024217; fetched 2026-09-10 Product monograph INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024225; fetched 2026-09-10 Product monograph INSULIN ASPART · Limited Use, codes 646 (1), General benefit (4) 1 Indications NOVORAPID® (insulin aspart) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10 Product monograph • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. NOVORAPID® should normally be used in regimens together with an intermediate or long-acting insulin. NOVORAPID® (10 mL vials) may also be used for continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for insulin infusion. PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10 Product monograph INSULIN HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024233; fetched 2026-09-10 Product monograph INSULIN LISPRO · Limited Use, codes 646 (1), General benefit (4) INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02229704; fetched 2026-09-10 Product monograph INSULIN LISPRO & INSULIN LISPRO PROTAMINE · General benefit INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS NovoMix® 30 (30% soluble insulin aspart and 70% insulin aspart protamine crystals) is indicated for:  The treatment of adult patients with diabetes mellitus who require insulin for the control of hyperglycemia. 1.1 Pediatrics Pediatrics (<16 years of age): No adequate data are available to establish the effectiveness in pediatrics. 1.2 Geriatrics Geriatrics (>65 years of age): Clinical studies of NovoMix® 30 did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. https://pdf.hres.ca/dpd_pm/00062479.PDF PM date: JUL 11, 2017 Source product: NOVOMIX 30; DIN 02265435; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.